Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34.

PMID:
15752881
2.

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.

Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1056-65.

PMID:
15519775
3.

Fractionation and late rectal toxicity.

Brenner DJ.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1013-5. No abstract available.

PMID:
15519768
4.

Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.

De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W.

Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):777-87. Review.

PMID:
15465194
5.

Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol.

Mott JH, Livsey JE, Logue JP.

Br J Radiol. 2004 May;77(917):377-86.

PMID:
15121701
6.

Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.

Karlsdóttir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O.

Radiother Oncol. 2004 Apr;71(1):43-53.

PMID:
15066295
7.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):735-42.

PMID:
14967428
8.

Prostate cancer radiotherapy dose response: an update of the fox chase experience.

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE.

J Urol. 2004 Mar;171(3):1132-6.

PMID:
14767286
9.

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.

Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, Logue JP.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1254-9.

PMID:
14630259
10.
11.

A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate.

Price RA, Murphy S, McNeeley SW, Ma CM, Horwitz E, Movsas B, Raben A, Pollack A.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):843-52.

PMID:
14529792
12.

Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.

Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, Shimizu S, Nonomura K, Koyanagi T, Miyasaka K.

Cancer J. 2003 Jul-Aug;9(4):268-76.

PMID:
12967137
13.

Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA.

World J Urol. 2003 Sep;21(4):200-8. Epub 2003 Sep 5. Review.

PMID:
12961097
14.

How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194-203.

Fowler JF, Ritter MA, Fenwick JD, Chappell RJ.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):593-5; author reply 595-6. No abstract available.

PMID:
12957275
15.

Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.

Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):391-401.

PMID:
12957250
16.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413.

J Clin Oncol. 2003 May 15;21(10):1904-11.

PMID:
12743142
17.

How low is the alpha/beta ratio for prostate cancer?

Wang JZ, Guerrero M, Li XA.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203.

PMID:
12504054
18.

Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.

Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, Kuban DA.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1314-21.

PMID:
12459352
19.

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M 3rd, Sandler HM, Pollack A, Cox JD.

Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1036-46.

PMID:
12419429
20.

Yes, the alpha/beta ratio for prostate cancer is low or "methinks the lady doth protest too much...about a low alpha/beta that is".

King CR, Fowler JF.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):626-7; author reply 627-8. No abstract available.

PMID:
12243843
Items per page

Supplemental Content

Write to the Help Desk